BrightGene Bio's market value is the price at which a share of BrightGene Bio trades on a public exchange. It measures the collective expectations of BrightGene Bio Medical investors about its performance. BrightGene Bio is trading at 29.55 as of the 14th of January 2025, a 2.36 percent increase since the beginning of the trading day. The stock's open price was 28.87. With this module, you can estimate the performance of a buy and hold strategy of BrightGene Bio Medical and determine expected loss or profit from investing in BrightGene Bio over a given investment horizon. Check out BrightGene Bio Correlation, BrightGene Bio Volatility and BrightGene Bio Alpha and Beta module to complement your research on BrightGene Bio.
Please note, there is a significant difference between BrightGene Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if BrightGene Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BrightGene Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
BrightGene Bio 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to BrightGene Bio's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of BrightGene Bio.
0.00
12/15/2024
No Change 0.00
0.0
In 31 days
01/14/2025
0.00
If you would invest 0.00 in BrightGene Bio on December 15, 2024 and sell it all today you would earn a total of 0.00 from holding BrightGene Bio Medical or generate 0.0% return on investment in BrightGene Bio over 30 days. BrightGene Bio is related to or competes with JCHX Mining, China Mobile, Shanghai CEO, Queclink Wireless, Fiberhome Telecommunicatio, and Beijing Bewinner. BrightGene Bio is entity of China. It is traded as Stock on SHG exchange. More
BrightGene Bio Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure BrightGene Bio's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess BrightGene Bio Medical upside and downside potential and time the market with a certain degree of confidence.
Today, many novice investors tend to focus exclusively on investment returns with little concern for BrightGene Bio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as BrightGene Bio's standard deviation. In reality, there are many statistical measures that can use BrightGene Bio historical prices to predict the future BrightGene Bio's volatility.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as BrightGene Bio. Your research has to be compared to or analyzed against BrightGene Bio's peers to derive any actionable benefits. When done correctly, BrightGene Bio's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in BrightGene Bio Medical.
BrightGene Bio Medical Backtested Returns
At this point, BrightGene Bio is not too volatile. BrightGene Bio Medical secures Sharpe Ratio (or Efficiency) of 0.0141, which signifies that the company had a 0.0141% return per unit of risk over the last 3 months. We have found twenty-two technical indicators for BrightGene Bio Medical, which you can use to evaluate the volatility of the firm. Please confirm BrightGene Bio's Standard Deviation of 3.74, mean deviation of 2.6, and Risk Adjusted Performance of (0.01) to double-check if the risk estimate we provide is consistent with the expected return of 0.0525%. BrightGene Bio has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.34, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BrightGene Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding BrightGene Bio is expected to be smaller as well. BrightGene Bio Medical right now shows a risk of 3.73%. Please confirm BrightGene Bio Medical standard deviation, jensen alpha, and the relationship between the coefficient of variation and information ratio , to decide if BrightGene Bio Medical will be following its price patterns.
Auto-correlation
0.59
Modest predictability
BrightGene Bio Medical has modest predictability. Overlapping area represents the amount of predictability between BrightGene Bio time series from 15th of December 2024 to 30th of December 2024 and 30th of December 2024 to 14th of January 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of BrightGene Bio Medical price movement. The serial correlation of 0.59 indicates that roughly 59.0% of current BrightGene Bio price fluctuation can be explain by its past prices.
Correlation Coefficient
0.59
Spearman Rank Test
0.45
Residual Average
0.0
Price Variance
0.32
BrightGene Bio Medical lagged returns against current returns
Autocorrelation, which is BrightGene Bio stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting BrightGene Bio's stock expected returns. We can calculate the autocorrelation of BrightGene Bio returns to help us make a trade decision. For example, suppose you find that BrightGene Bio has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values
Timeline
BrightGene Bio regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If BrightGene Bio stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if BrightGene Bio stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in BrightGene Bio stock over time.
Current vs Lagged Prices
Timeline
BrightGene Bio Lagged Returns
When evaluating BrightGene Bio's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of BrightGene Bio stock have on its future price. BrightGene Bio autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, BrightGene Bio autocorrelation shows the relationship between BrightGene Bio stock current value and its past values and can show if there is a momentum factor associated with investing in BrightGene Bio Medical.
Other Information on Investing in BrightGene Stock
BrightGene Bio financial ratios help investors to determine whether BrightGene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BrightGene with respect to the benefits of owning BrightGene Bio security.